Publication Topic

Kirman CR, Suh M, Proctor DM, Hays SM. 2017. Improved physiologically based pharmacokinetic model for oral exposures to chromium in mice, rats, and humans to address temporal variation and sensitive populations. Toxicol Appl Pharmacol 325(15 June):9-17; doi: 10.1016/j.taap.2017.03.023.

Borghoff SJ, Ring C, Banton MI, Leavens TL. Ethyl tertiary butyl ether (ETBE) and tertiary butyl alcohol (TBA) physiologically based pharmacokinetic (PBPK) model in rats: Contribution of binding to 2u-globulin and non-linear kinetics to kidney and liver responses in rats. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Kirman CR, Proctor D, Suh M, Haws L, Harris M, Thompson C, Hays S. Using physiologically based pharmacokinetic modeling to address potentially sensitive subpopulations exposed to hexavalent chromium. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Covington TR, Pangburn HA, Mayes RS, Ott DK, Gearhart JM. Estimated inter-individual variations in high-performance aircraft pilot exposures using physiologically-based pharmacokinetic (PBPK) modeling and Monte Carlo analysis. Poster presented at Society of Toxicology 56th Annual Meeting, Baltimore, MD, March 2017.

Wilson JE, Kurukulasuriya R, Sinz C, Matthew Lombardo, Kate Bender, Dann Parker, … Dingley K, et al. 2016. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes. Bioorg Med Chem Lett 26(12):2947–2951; doi: 10.1016/j.bmcl.2016.04.018. PMID: 27240550.

Campbell J, Franzen A, Van Landingham C, Lumpkin M, Crowell S, Meredith C, Loccisano A, Gentry R, Clewell H. 2016. Predicting lung dosimetry of inhaled particle-borne benzo(a)pyrene using physiologically based pharmacokinetic modeling. Inhal Toxicol 28(11):520–535; doi: 10.1080/08958378.2016.1214768.

Chang X, Kleinstreuer N, Ceger P, Choksi NY, Hseih J, DeVito M, Allen DG, Casey W. Application of reverse dosimetry to compare in vitro and in vivo estrogen receptor activity. Poster presented at Society of Toxicology 54th Annual Meeting, San Diego, CA, March 2015.

Unice KM, Kerger BD, Paustenbach DJ, Finley BL, Tvermoes BE. 2014. Refined biokinetic model for humans exposed to cobalt dietary supplements and other sources of systemic cobalt exposure. Chem-Biol Interact 216:53–74; doi: 10.1016/j.cbi.2014.04.001. PMID: 24726710.

Kirman CR, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM, Lin SS, Parker W, Hays SM. 2013. Physiologically based pharmacokinetic model for humans orally exposed to chromium. Chem Biol Interact 204(1):13-27; doi: 10.1016/j.cbi.2013.04.003.

Kirman CR, Thompson CM, Proctor DM, Suh M, Haws LC, Harris MA, Hays SM. Using PBPK modeling to address diurnal variation and age differences in hexavalent chromium toxicokinetics in humans. Presented at Society of Toxicology 52nd Annual Meeting,San Antonio, TX, March 2013.

Kirman CR, Hays SM, Aylward LL, Suh M, Harris MA, Thompson CM, Haws LC, Proctor DM. 2012. Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium. Chem Biol Interact 200(1):45-64; doi: 10.1016/j.cbi.2012.08.016.

Kirman CR, Hays SM, Aylward LL, Suh M, Proctor D. 2012. Physiologically-based pharmacokinetic model for mice, rats and humans orally-exposed to chromium. Presented at Society of Toxicology 51st Annual Meeting, San Francisco, CA, March 2012.

Urban J, Budinsky R, Rowlands J. 2012. An evaluation of single nucleotide polymorphisms in the human heat shock protein 90kDa alpha and beta isoforms. Drug Metab Pharmacokinet 27(2):268-278; doi: 10.2133/dmpk.DMPK-11-SC-114.

Proctor D, Haws L, Thompson C, Harris M. 2011. Use of mode of action and pharmacokinetics to inform the cancer risk assessment of ingested Cr(VI): A case study. Presented at the Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.

Covington T, Robinson P, Gearhart J. Exploring issues in simulating dermal exposure using a physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) model for VX. Poster presented at the Chemical and Biological Defense Science and Technology Conference, Orlando, FL, November 2010.

Covington TR, Jakubowski EM, McGuire JM, Byers CE, Evans RA, Hulet SW, et al. A multi-species and -route ion- and isomer-specific physiologically-based pharmacokinetic-pharmacodynamic model for VX. Presentation at the Chemical and Biological Defense Science and Technology Conference, Dallas, TX, November 2009.

Thompson CM, Johns DO, Sonawane S, Barton HA, Hattis D, Tardif R, Krishnan K. 2009. Database for physiologically based pharmacokinetic (PBPK) modeling: Physiological parameters for healthy and health-impaired elderly. J Toxicol Environ Health B 12(1):1–24; doi: 10.1080/10937400802545060.

Thompson CM, Sonawane B, Barton HA, DeWoskin RS, Schlosser P, Lipscomb JC, Chiu W, Krishnan K. 2008. Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J Toxicol Environ Health B 11(7):519–547; doi: 10.1080/10937400701724337.

Emond C, Raymer J, Garner E, Diliberto J, Staskal D, Birnbaum LS. A physiologically-based pharmacokinetic model for developmental exposure to PBDE-47 in rodents. Society of Toxicology 46th Annual Meeting, Charlotte, NC, March 2007.

Hack CE, Covington TR, Lawrence G, Shipp AM, Gentry R, Yager J, Clewell, HJ, III. 2007. A pharmacokinetic model of the intracellular dosimetry of inhaled nickel. J Toxicol Environ Health A 70(5):445–464; doi: 10.1080/15287390600870726.